BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal Expanding Rare Disease and Immunology Portfolio

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a...

June 02, 2025 | News

Kexing Biopharm’s GB18 Receives IND Approval in China and U.S. for Cancer Cachexia Treatment

Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) applica...

May 30, 2025 | News

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...

May 21, 2025 | News

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

Xuanzhu Biopharmaceutical’s Bireociclib (Xuanyuening®) Approved in China, Setting New Benchmark in HR+/HER2- Breast Cancer Treatment

National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...

May 19, 2025 | News

Agilent and Ubix Therapeutics Join Forces to Advance Targeted Cancer Therapies in South Korea

Research focuses on targeted protein degradation and antibody-drug conjugate as promising modalities for developing next-generation cancer therapies ...

May 15, 2025 | News

Hyundai ADM Bio Withdraws IND for Penetrium™/Docetaxel and Pivots to Immunotherapy Combinations

Hyundai ADM Bio announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Pene...

May 14, 2025 | News

Gene Solutions Validates K-TRACK™ ctDNA Test as Prognostic Biomarker

Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-worl...

May 12, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

TAE Life Sciences and Ohio State Forge Landmark BNCT Partnership to Advance Next-Generation Boron-Based Cancer Therapies

TAE Life Sciences (TLS) announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center – ...

May 05, 2025 | News

Merck to Acquire SpringWorks Therapeutics for $3.9 Billion, Strengthening Rare Tumor Leadership

Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 bill...

April 28, 2025 | News

Primo Biotechnology Secures PIC/S GMP and GDP Certifications, Strengthening Global Position in Nuclear Medicine

Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Dr...

April 25, 2025 | News

GC Cell Secures Exclusive Rights to DAAN Biotherapeutics’ Tumor Antigen-Specific Antibody for CAR-T and CAR-NK Therapies

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusi...

April 22, 2025 | News

Stay Connected